A Strategic Pivot with Teeth: Why Amati AIM VCT’s Triple Play Matters
When a seasoned VCT makes a manager change, overhauls its strategy, and fires off a double-digit special dividend all in one RNS? That’s not just housekeeping – it’s a full-scale reinvention. Let’s unpack what’s really happening beneath the spreadsheet poetry.
The Managerial Handoff: From Amati to Maven
After 15 years at the helm, Amati Global Investors is passing the baton to Maven Capital Partners effective 1 May 2025. This isn’t just a changing of the guard – it’s a philosophical shift:
- Why Maven? Their £800m+ private equity expertise aligns perfectly with the new “AIM Plus” strategy
- The Subtext: AIM’s new issue market has been on life support since 2022, with IPO volumes down 78%
- Portfolio Reality Check: Only 3 of the current top 10 holdings were acquired post-2018 VCT rule changes
‘AIM Plus’ – More Than Just a Marketing Slogan
The proposed shift to invest 30%+ in private companies alongside AIM holdings isn’t just diversification – it’s survival instinct. Consider:
The Numbers Don’t Lie
£10m invested in qualifiers during FY25 vs £13.3m previous year. But here’s the kicker – £6.6m of that went into 7 new holdings, mostly secondary placings in distressed AIM names. The pipeline’s drying up faster than a puddle in the Sahara.
Special Dividends: Returning Cash or Signaling Retreat?
That juicy 10p special dividend (12.9% yield on NAV) tells its own story:
| FY2025 Dividends | Amount (p) | NAV Coverage |
|---|---|---|
| Special (May ’24) | 10.0 | 10.9% |
| Interim (Sep ’24) | 2.5 | 2.7% |
| Second Interim (Jan ’25) | 1.5 | 1.6% |
With £22.1m in cash (19.8% of NAV), shareholders are essentially being paid to wait through the transition.
Portfolio Crossroads: Winners vs Zombies
The FY25 portfolio reveals a tale of two strategies:
Success Stories
- SRT Marine: +62% on £1.2m holding
- Diaceutics: 31% gain as ARR hits £17m
- Keywords Studios: £9.8m exit at 20x return
Problem Children
- Aurrigo: -51% after emergency raise
- Sosandar: -55% as stores strategy stumbles
- Fusion Antibodies: £2.4m cost vs £363k value
The Trump Card No One Wanted
Chairman Fiona Wollocombe’s outlook statement contains more red flags than a bullfighting convention:
“The start of President Trump’s second term… has been seismic and chaotic for markets… destabilising the transatlantic alliance on which the peace and prosperity of the Post-World War II era has been based.”
For AIM’s micro-caps, this geopolitical turbulence compounds existing pressures from:
- Reduced IHT benefits for AIM shares
- UK’s 10-year gilt yields spiking to 4.5%
- Labour’s “tax and spend” budget denting confidence
Bottom Line: High Stakes Transition
This triple move feels like a controlled demolition – dismantling the old AIM-dependent model before it collapses under its own weight. The key questions for shareholders:
- Can Maven’s private equity prowess offset AIM’s structural decline?
- Will the 30% private allocation limit prove too restrictive?
- Is the 6% proposed dividend policy sustainable amidst reinvention?
One thing’s certain – in the words of departing manager Paul Jourdan: “We hand it on with sadness.” For investors, the next chapter promises either renaissance or requiem.
